Biopharma Business

Tag "lung cancer"

Tarloxitinib puts tumour-seeking tail on anti-EGFR drug to target lung cancer

    Tarloxitinib puts tumour-seeking tail on anti-EGFR drug to target lung cancer

EGFR is a common genetic target in lung cancer, but not all EGFR mutations are created equal. Patients with a type of EGFR anomaly called an “EGFR exon 20 insertion”

Read Full Article

Novartis’ lung cancer drug combination receives EU approval

The European Commission has approved Novartis’ Tafinlar (dabrafenib) in combination with Mekinist (trametinib) for the treatment of patients with BRAF V600-positive advanced or metastatic non-small cell lung cancer (NSCLC). The

Read Full Article

Antioxidants and lung cancer risk

An epidemiological study published in Frontiers in Oncology suggests that a diet high in carotenoids and vitamin C may protect against lung cancer. The study authors found that vitamin C

Read Full Article

Emory scientists map ‘spiderweb’ of lung cancer proteins to snare new drug targets

Scientists at Emory University’s Winship Cancer Institute are on a mission to unlock the mysteries of lung cancer cells that have long been thought to be unresponsive to any drug

Read Full Article

Upcoming Events

  • No upcoming events
AEC v1.0.4

The Magazine

New Subscriber





Subscribe Here



Advertisements